Clinical Trials Logo
  1. Home
  2. IPF
  3. NCT06310746

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects

IPF Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Phase I Clinical Study to Assess the Safety, Pharmacokinetics, and Immunogenicity of HLX6018 in Healthy Subjects

Clinical Trial Summary

The purpose of this study is to investigate the safety, PK, and immunogenicity of a single intravenous administration of HLX6018 in healthy subjects, based on the preliminary efficacy and safety established through in vitro and in vivo experiments. This is a randomized, double-blind, placebo-controlled study with single dose escalation design to assess the safety, PK, and immunogenicity of HLX6018 in healthy subjects. It is planned to enroll 8-10 subjects in each of seven dose groups (0.25 mg/kg, 1.0 mg/kg, 4.0 mg/kg, 12 mg/kg, 25 mg/kg, 50 mg/kg, and 70 mg/kg). This is the first-in-human study of the investigational product.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06310746
Study type Interventional
Source Shanghai Henlius Biotech
Contact Yanhua Ding
Email dingyanhua2003@126.com
Status Recruiting
Phase Phase 1
Start date April 23, 2024
Completion date December 30, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05570058 - Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Recruiting NCT05895565 - A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects Phase 1
Completed NCT03211507 - Idiopathic Pulmonary Fibrosis Job Exposures Study
Completed NCT02503657 - Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Recruiting NCT03873298 - Inhaled NO in IPF and COPD During 6 Minute Walk Test Phase 2
Terminated NCT03864328 - A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF Phase 2
Completed NCT05803850 - A Study to Evaluate the Safety, Tolerability, PK and PD of HNC1058 Phase 1
Withdrawn NCT05349760 - A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT01266317 - Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 1/Phase 2
Recruiting NCT05147597 - Turkish Validity and Reliability of SGRQ-I
Completed NCT04503044 - ILAs in CT Lung Cancer Screening Population
Recruiting NCT04564183 - Advancing Prevention of Pulmonary Fibrosis
Recruiting NCT05190211 - Telerehabilitation in Patients With Idiopathic Pulmonary Fibrosis N/A
Recruiting NCT04263727 - A Study of Patients With Chronic Disease
Completed NCT05353556 - Effects of Home-based Inspiratory Muscle Training in Patients With IPF N/A
Completed NCT02976935 - Functional MR Lung Imaging Using Hyperpolarised 129Xe
Recruiting NCT05193136 - Sleep Hygiene, Sarcopenia, and Cognitive Function in Respiratory Disease
Recruiting NCT06181370 - Phase I Study to Assess Safety, Tolerability, PK and PD of AGMB-447 in Healthy Participants and Participants With IPF Phase 1
Not yet recruiting NCT02885961 - The Coagulation Cascade in Idiopathic Pulmonary Fibrosis N/A